Press Releases InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance March 27, 2026 Read More » InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program March 23, 2026 Read More » InMed Provides Update on Pharmaceutical Development Programs – Advancing Lead Drug Candidates Towards IND and Clinical Trial March 9, 2026 Read More » InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline March 6, 2026 Read More » InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update February 11, 2026 Read More » InMed Announces Results of 2025 Annual General and Special Meeting December 17, 2025 Read More » InMed Provides Update on BayMedica Commercial Business December 12, 2025 Read More » InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 November 18, 2025 Read More » InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update November 6, 2025 Read More » Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors October 16, 2025 Read More » InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors October 9, 2025 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update September 23, 2025 Read More » InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025 September 16, 2025 Read More » InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 Read More » InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 July 28, 2025 Read More » InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules June 27, 2025 Read More » InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 25, 2025 Read More » InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study June 24, 2025 Read More » InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA June 13, 2025 Read More » InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update May 12, 2025 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance March 27, 2026 Read More »
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program March 23, 2026 Read More »
InMed Provides Update on Pharmaceutical Development Programs – Advancing Lead Drug Candidates Towards IND and Clinical Trial March 9, 2026 Read More »
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline March 6, 2026 Read More »
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update February 11, 2026 Read More »
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 November 18, 2025 Read More »
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update November 6, 2025 Read More »
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors October 16, 2025 Read More »
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors October 9, 2025 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update September 23, 2025 Read More »
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025 September 16, 2025 Read More »
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 Read More »
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 July 28, 2025 Read More »
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules June 27, 2025 Read More »
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 25, 2025 Read More »
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study June 24, 2025 Read More »
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA June 13, 2025 Read More »
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update May 12, 2025 Read More »
